title: [Reduction of HIV mother-to-child transmission in Colombia, two years of experience, 2003-2005].
abstract: BACKGROUND
  A national initiative on reduction of HIV mother-to-child-transmission is being implemented since 2003 in Colombia, including HIV counseled and voluntary testing as part of the routine antenatal care, comprehensive care with ARV treatment to HIV-positive pregnant women and their infected children, caesarian delivery, and replacement of breast milk.
  
  
  OBJECTIVE
  To describe the achievements in the implementation of the prevention strategy of mother-to-child HIV transmission, 2003-2005.
  
  
  METHODS
  The implementation procedures of the Project are described, as well as the coverage percentages achieved, the prevention of vertical transmission and its associated factors, and the six-month prevalence by geographical departments. The probability of transmission adjusted to the ARV treatment offered and the differences by regions are also analyzed.
  
  
  RESULTS
  The Project was implemented in 757 municipalities (68%); diagnostic tests were performed to 200,853 pregnant women, 377 of whom were diagnosed as HIV positive (0.19%), with higher prevalences in the Caribbean region, and in the Departments of Quindio and Santander. Complete six-month follow-up after delivery was provided to 285 women and their neonates (12 of whom were HIV-positive). The probability of transmission with the use of ARV schemes during pregnancy (n=170) was 1.78% (IC 95%: 0.37-5.13%). Factors related to probability of transmission were: initial viral load > 10,000/mm3, absence of antenatal care, and late recruitment of pregnant women. No statistical differences were found between the ARV schemes used. In the Caribbean region, antenatal care was lower, and late recruitment of pregnant women was higher.
  
  
  CONCLUSIONS
  Reduction of HIV mother-to-child-transmission is an effective preventive intervention, which also strengthens the quality of antenatal care services. Sustainability of this initiative, with nationwide coverage, must be a target for national and regional public health authorities, and for health care providers.
authors.affiliation: Onusida-Colombia, Bogotá, D.C., Colombia. proyectomadrehijo@yahoo.com
authors.forename: Ricardo
authors.initials: R
authors.lastname: García
authors.forename: Franklyn
authors.initials: F
authors.lastname: Prieto
authors.forename: Carlos
authors.initials: C
authors.lastname: Arenas
authors.forename: Julio
authors.initials: J
authors.lastname: Rincón
authors.forename: Sidia
authors.initials: S
authors.lastname: Caicedo
authors.forename: Gloria
authors.initials: G
authors.lastname: Rey
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D003105:Colombia / Q000453:epidemiology; D005260:Female; D005315:Fetal Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000453:epidemiology; D011295:Prenatal Care; D011296:Prenatal Diagnosis
chemical_list: D019380:Anti-HIV Agents